Moleculin Biotech, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the supplied filing text.
Business context
Moleculin is a clinical-stage pharmaceutical company with no approved products and no product-sales revenue. Its development programs target difficult-to-treat cancers and viruses, using technologies licensed primarily from MD Anderson. The company’s principal internal priorities are Annamycin for soft-tissue sarcoma lung metastases and relapsed/refractory acute myeloid leukemia (AML), plus improved delivery of WP1066. It aims to use external funding and collaborations where possible.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $19.0 million | $14.4 million |
| General and administrative expense | $11.5 million | $8.4 million |
| Total operating expenses | $30.6 million | $23.0 million |
| Operating loss | $30.6 million | $23.0 million |
| Net loss | $29.0 million | $15.9 million |
| Net loss per share, basic and diluted | $1.01 | $0.59 |
| Cash used in operating activities | $27.6 million | $19.0 million |
Cash and cash equivalents were $43.1 million at year-end, down from $70.9 million. Current assets were $45.6 million and current liabilities $4.8 million. Total liabilities were $5.2 million, comprising current liabilities, lease liabilities and a $0.1 million warrant liability; the filing does not report conventional borrowings. With no revenue, gross profit and operating margins are not meaningful.
There were no net proceeds from financing activities in 2022; 2021 financing provided $74.7 million, primarily from an equity offering. Management estimated year-end cash would fund projected operating requirements into the third quarter of 2024, subject to changes in development plans and unplanned costs. The company expects continued losses and negative operating cash flow.
Material changes and operating developments
- R&D expense increased $4.6 million, mainly from greater clinical-trial activity and manufacturing additional drug product. G&A increased $3.1 million, largely from regulatory and legal services and consulting and advisory fees.
- The net loss rose by $13.1 million. A noncash gain from revaluing warrant liabilities fell to $1.3 million from $6.7 million in 2021, contributing to the larger reported loss.
- Cash declined by $27.8 million during 2022, primarily reflecting higher operating cash use. The company reported no material investing outlays.
- Annamycin’s single-agent AML Phase 1 study in Europe established a recommended Phase 2 dose of 240 mg/m². The final cohort of five subjects had an 80% overall response rate (three partial responses and one CRi); the company shifted focus to a combination trial with cytarabine rather than expanding the single-agent study.
- In the Annamycin soft-tissue sarcoma lung-metastases study, Phase 1 results were preliminary: 9 of 15 subjects had stable disease or better after at least two cycles, with median progression-free survival of 2.6 months. In the ongoing Phase 2 portion, 4 of 6 assessed subjects had stable disease or better after two cycles. These findings are early and may change.
- WP1122’s UK Phase 1a healthy-volunteer study concluded in 2022, establishing a reported maximum tolerated daily dose of 32 mg/kg in two divided doses for seven days. The study report was still being finalized. The company said further WP1122 trials would depend on external funding.
- A physician-sponsored WP1066 pediatric brain-tumor trial concluded in February 2023. The company reported no drug-related serious adverse events and a temporary clinical response in one DIPG subject; this is preliminary single-subject evidence, not proof of efficacy.
Outlook, risks and unusual items
- Funding: Management stated existing capital is insufficient to complete development and commercialization. Additional financing may be needed and could be unavailable, costly or dilutive; a shortfall could force reductions or delays to programs.
- SEC subpoena: The company disclosed a March 2022 SEC subpoena seeking documents related to certain individuals and entities and to development of and statements about its COVID-19 candidate. The company said it does not know the investigation’s specific nature and cannot predict its outcome. It expensed approximately $2.4 million in related legal fees in 2022 and estimated about $1 million of additional legal costs in 2023. The subpoena does not itself indicate that the SEC concluded a violation occurred.
- WPD sublicense termination: In March 2023, after year-end, Moleculin and WPD agreed to terminate their sublicense. Moleculin agreed to pay $700,000 in cash and issue $800,000 of common stock; WPD assigned its rights and obligations in a grant-funded Annamycin sarcoma trial to Moleculin. The company said it then held worldwide rights to its licensed intellectual property, except non-human-animal rights.
- Clinical and execution risk: All programs remain early-stage, and preliminary trial findings may not be reproduced or support approval. Recruitment, trial-site staffing, drug supply, regulatory requirements, manufacturing and third-party or investigator-led trial execution can cause delays or added costs.
- Other risks: Moleculin relies on third parties for manufacturing, including a single source for Annamycin API; the composition-of-matter patent for Annamycin has expired; its $11.1 million in-process R&D intangible asset could be impaired if development is abandoned. The company also identifies geopolitical disruption, including the war in Ukraine, and lingering pandemic-related effects as potential operational risks.
- Related-party matters: The filing describes historical related-party transactions that were not conducted at arm’s length, including relationships involving WPD, ALI and HPI. Review the relevant agreements and governance disclosures.
Other key disclosures
The financial statements received an unmodified independent auditor’s opinion. The auditor reported no critical audit matters and did not attest to internal-control effectiveness. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2022. Year-end common shares outstanding were 28.6 million; the filing also disclosed 5.6 million options and warrants outstanding in aggregate in its risk discussion, creating potential dilution.
Most important facts for investors to verify
- Cash, operating cash burn and the assumptions behind management’s projected runway into Q3 2024; assess subsequent financing and spending.
- Final clinical-study reports and updated, independently verifiable efficacy and safety data, especially for Annamycin AML and sarcoma trials and the WP1066 pediatric response.
- Status and potential outcome of the SEC inquiry, including subsequent requests, legal costs and any later company or SEC disclosures.
- Completion and financial terms of the WPD termination, stock issuance and transfer of the grant-funded trial, as well as the practical value and enforceability of worldwide IP rights.
- Potential dilution from outstanding options and warrants and any subsequent equity issuance or financing.